

WIP (h): 293T Lysate: sc-111797

BACKGROUND

Mutations in the Wiskott-Aldrich syndrome protein (WASP) often result in immunodeficiency due to abnormal T cell and B cell activation. The 503 amino acid WAS-interacting protein (WIP) contains a number of domains implicated in Actin-binding and several putative Src homology-binding domains. The first 100 amino acids of WASP interact with amino acids 377-503 of WIP and the majority of pathogenic mutations associated with WAS occur within the first 100 amino acids of WASP. The gene encoding human WIP maps to chromosome 2q31.1. Overexpression of WIP in the human B cell line BJAB increases F-Actin content and cerebriform projections. While both WIP and Vav cooperate in the regulation of NFAT/AP-1 gene transcription, the WIP-WASP complex is required for activation of NFAT/AP-1 necessary for proper T cell function. A dysfunctional WIP-WASP complex may be implicated in the immunodeficient phenotype in WAS.

REFERENCES

- Cooper, M.D., Chase, H.P., Lowman, J.T., Krivit, W. and Good, R.A. 1968. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. *Am. J. Med.* 44: 499-513.
- Derry, J.M., Ochs, H.D. and Francke, U. 1994. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. *Cell* 78: 635-644.
- Schwarz, K., Nonoyama, S., Peitsch, M., de Saint Basile, G., Espanol, T., Fasth, A., Fischer, A., Freitag, K., Friedreich, W. and Fugmann, S. 1996. WASPbase: a database of WAS- and XLT-causing mutations. *Immunol. Today* 17: 496-502.
- Narayanaswamy, R., Anto, I.M., Hartwig, J.H. and Geha, R.S. 1997. WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces Actin polymerization and redistribution in lymphoid cells. *Proc. Natl. Acad. Sci. USA* 94: 14671-14676.
- Stewart, D.M., Tian, L. and Nelson, D.L. 1999. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. *J. Immunol.* 162: 5019-5024.
- Savoy, D.N., Billadeau, D.D. and Leibson, P.J. 2000. Cutting edge: WIP, a binding partner for Wiskott-Aldrich syndrome protein, cooperates with Vav in the regulation of T cell activation. *J. Immunol.* 164: 2866-2870.

CHROMOSOMAL LOCATION

Genetic locus: WIPF1 (human) mapping to 2q31.1.

PRODUCT

WIP (h): 293T Lysate represents a lysate of human WIP transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

WIP (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive WIP antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

WIP (A-7): sc-271113 is recommended as a positive control antibody for Western Blot analysis of enhanced human WIP expression in WIP transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



WIP (A-7): sc-271113. Western blot analysis of WIP expression in non-transfected: sc-117752 (A) and human WIP transfected: sc-111797 (B) 293T whole cell lysates.



WIP (E-9): sc-271114. Western blot analysis of WIP expression in non-transfected: sc-117752 (A) and human WIP transfected: sc-111797 (B) 293T whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.